347 related articles for article (PubMed ID: 30973134)
1. [Anti-cancer vaccines: What future in anti-cancer immunotherapy strategies?].
Tartour E
Biol Aujourdhui; 2018; 212(3-4):69-76. PubMed ID: 30973134
[TBL] [Abstract][Full Text] [Related]
2. Intratumoral immunotherapy: using the tumor as the remedy.
Marabelle A; Tselikas L; de Baere T; Houot R
Ann Oncol; 2017 Dec; 28(suppl_12):xii33-xii43. PubMed ID: 29253115
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic cancer vaccine: building the future from lessons of the past.
Tran T; Blanc C; Granier C; Saldmann A; Tanchot C; Tartour E
Semin Immunopathol; 2019 Jan; 41(1):69-85. PubMed ID: 29978248
[TBL] [Abstract][Full Text] [Related]
4. CD27 Agonism Plus PD-1 Blockade Recapitulates CD4+ T-cell Help in Therapeutic Anticancer Vaccination.
Ahrends T; Bąbała N; Xiao Y; Yagita H; van Eenennaam H; Borst J
Cancer Res; 2016 May; 76(10):2921-31. PubMed ID: 27020860
[TBL] [Abstract][Full Text] [Related]
5. [Cancer immunotherapy: Rational and recent breakthroughs].
Granier C; Karaki S; Roussel H; Badoual C; Tran T; Anson M; Fabre E; Oudard S; Tartour E
Rev Med Interne; 2016 Oct; 37(10):694-700. PubMed ID: 27370898
[TBL] [Abstract][Full Text] [Related]
6. Adding fuel to the fire: immunogenic intensification.
O'Sullivan Coyne G; Gulley JL
Hum Vaccin Immunother; 2014; 10(11):3306-12. PubMed ID: 25483630
[TBL] [Abstract][Full Text] [Related]
7. [Immunological tumor therapy].
Dietrich K; Theobald M
Internist (Berl); 2015 Aug; 56(8):907-16; quiz 917. PubMed ID: 26187335
[TBL] [Abstract][Full Text] [Related]
8. The present status and future prospects of peptide-based cancer vaccines.
Hirayama M; Nishimura Y
Int Immunol; 2016 Jul; 28(7):319-28. PubMed ID: 27235694
[TBL] [Abstract][Full Text] [Related]
9. Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: Preclinical studies with MVA-βGal and MVA-MUC1 (TG4010) in a murine tumor model.
Remy-Ziller C; Thioudellet C; Hortelano J; Gantzer M; Nourtier V; Claudepierre MC; Sansas B; Préville X; Bendjama K; Quemeneur E; Rittner K
Hum Vaccin Immunother; 2018 Jan; 14(1):140-145. PubMed ID: 28925793
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy.
McArthur HL; Page DB
Clin Adv Hematol Oncol; 2016 Nov; 14(11):922-933. PubMed ID: 27930644
[TBL] [Abstract][Full Text] [Related]
11. Harnessing the immune system against cancer: current immunotherapy approaches and therapeutic targets.
Kumar AR; Devan AR; Nair B; Vinod BS; Nath LR
Mol Biol Rep; 2021 Dec; 48(12):8075-8095. PubMed ID: 34671902
[TBL] [Abstract][Full Text] [Related]
12. A paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting.
Gray A; Raff AB; Chiriva-Internati M; Chen SY; Kast WM
Immunol Rev; 2008 Apr; 222():316-27. PubMed ID: 18364011
[TBL] [Abstract][Full Text] [Related]
13. Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.
Sweis RF; Galsky MD
Urol Oncol; 2016 Dec; 34(12):556-565. PubMed ID: 27836246
[TBL] [Abstract][Full Text] [Related]
14. Cancer immunotherapy.
Schuster M; Nechansky A; Kircheis R
Biotechnol J; 2006 Feb; 1(2):138-47. PubMed ID: 16892244
[TBL] [Abstract][Full Text] [Related]
15. Combination Immunotherapy: Taking Cancer Vaccines to the Next Level.
Grenier JM; Yeung ST; Khanna KM
Front Immunol; 2018; 9():610. PubMed ID: 29623082
[TBL] [Abstract][Full Text] [Related]
16. [Cytotoxic T lymphocytes: role in immunosurveillance and in immunotherapy].
Benchetrit F; Gazagne A; Adotevi O; Haicheur N; Godard B; Badoual C; Fridman WH; Tartour E
Bull Cancer; 2003; 90(8-9):677-85. PubMed ID: 14609756
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic gene modified cell based cancer vaccines.
Kozłowska A; Mackiewicz J; Mackiewicz A
Gene; 2013 Aug; 525(2):200-7. PubMed ID: 23566846
[TBL] [Abstract][Full Text] [Related]
18. Combinatory therapy adopting nanoparticle-based cancer vaccination with immune checkpoint blockade for treatment of post-surgical tumor recurrences.
Chung CK; Da Silva CG; Kralisch D; Chan A; Ossendorp F; Cruz LJ
J Control Release; 2018 Sep; 285():56-66. PubMed ID: 30008371
[TBL] [Abstract][Full Text] [Related]
19. Mechanistic insights into the efficacy of cell penetrating peptide-based cancer vaccines.
Grau M; Walker PR; Derouazi M
Cell Mol Life Sci; 2018 Aug; 75(16):2887-2896. PubMed ID: 29508006
[TBL] [Abstract][Full Text] [Related]
20. Next generation approaches for tumor vaccination.
Patel A; Kaufman HL; Disis ML
Chin Clin Oncol; 2017 Apr; 6(2):19. PubMed ID: 28482672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]